ArticleJournal of hepatocellular carcinoma2026
Very Early Recurrence as a Dynamic Prognostic Stratifier After Curative Hepatectomy for Hepatocellular Carcinoma: A Landmark Analysis with Internal Validation and Machine-Learning Benchmarking.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Very early recurrence (VER, defined as recurrence within 12 months) after hepatocellular carcinoma (HCC) resection is often linked to poor survival, but conventional survival analyses stratified by recurrence status are inherently susceptible to guarantee-time bias. The relation between VER and post-recurrence survival also remains uncertain. Methods: This retrospective cohort included 526 patients with histopathologically confirmed HCC who underwent curative hepatectomy at the First Affiliated Hospital of Xinjiang Medical University between January 2016 and July 2025. A 12-month landmark cohort included patients alive beyond 12 months after surgery. Patients were split 7:3 into training and internally held-out validation cohorts. Landmark Cox models, a time-varying Cox model, post-recurrence survival analyses, and machine-learning benchmarking were performed. Missing primary-model values were median-imputed; multiple imputation was not used. Results: The landmark cohort included 486 patients; 82 had VER. The proportional-hazards assumption was violated for VER; the conventional adjusted Cox model estimated an average HR of 3.86 (95% CI, 2.81-5.29; P < 0.001) over post-landmark follow-up. The association varied over time, with model-estimated HRs of 10.06 at 1 month and 2.23 at 60 months after the landmark. In the internally held-out validation cohort, adding VER to the conventional Cox model improved the C-index from 0.591 (95% CI, 0.508-0.675) to 0.716 (95% CI, 0.633-0.797; C-index difference = 0.125, 95% CI, 0.051-0.203; P = 0.002). VER was not independently associated with post-recurrence mortality (HR, 1.23; 95% CI, 0.87-1.75; P = 0.25). Conclusions: Among patients alive at the 12-month landmark, VER was associated with higher subsequent mortality and improved discrimination in an internally held-out cohort. External validation is required before use for individual risk prediction or surveillance decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.